论文部分内容阅读
In the last decades,with the development of biological therapy,the treatment paradigms in patients with Crohn’s disease have continuously evolved.Several studies focusing on the optimal use of both traditional immunosupressants and biological therapy have been published,investigating conventional,accelerated step-up and topdown approaches.In addition,much emphasis has been placed in recent years on the determination of important predictive factors that could enable early patient stratification,which would lead to a tailored management strategy.In this review,the authors try to highlight new evidence on the optimal timing,benefits,and risks of immunosupressants alone,or in combination,in patients with Crohn’s disease.
In the last decades, with the development of biological therapy, the treatment paradigms in patients with Crohn’s disease have continuously evolved. Sewer studies focusing on the optimal use of both traditional immunosupressants and biological therapy have been published, investigating conventional, accelerated step-up and topdown approaches.In addition, much emphasis has been placed in recent years on the determination of important predictive factors that could enable early patient stratification, which would lead to a tailored management strategy. In this review, the authors try to highlight new evidence on the optimal timing, benefits, and risks of immunosupressants alone, or in combination, in patients with Crohn’s disease.